Does Every Breakpoint Revision or New Connection Need a 510(k)? The Conditions September 2026's PCCPs Set in Advance
The PCCP attached to bioMérieux's VITEK 2 AST cefepime card (K260619) is not described in the 510(k) Summary. The clearance letter names it, "Predetermined Change Control Plan for Breakpoint Evaluations, Version 01.B," and stops. FDA's own Decision Summary, the review record it publishes alongside the clearance, says more. The submission included a PCCP with a breakpoint change protocol, and that protocol "was reviewed and accepted by FDA in submission K250274 cleared on April 30, 2025." K250274 is the company's ETEST strip for imipenem/relebactam. A protocol accepted on one product is being referenced by later submissions.
This is part three of our monthly PCCP series. Part one listed September's eighteen PCCPs and part two read the seven that plan to retrain an AI model. This part looks not at whether a device uses AI but at plans for changes other than retraining. Of the eighteen, six could be confirmed from public information as plans to re-evaluate breakpoints, add an operating system, a data connection or compatible insulins, move a manufacturing site or extend use to more laboratories (VITEK 2 AST, iOS CamAPS FX, MODI System, Mint ACE Pump, TactiFlex, xT CDx), and two are flagged in FDA's record with no plan described in any public document (iLet, CDC's influenza panel). The remaining two, a 25G Huber needle and a set of administration sets, mention a PCCP only in the letter's standard paragraph, so part one notes them and this part leaves them aside. We trace the eight back through earlier filings and FDA's review documents.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles